Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 6c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.41), $0.06 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $19.22 million versus the consensus estimate of $15.37 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Goldman Sachs Reiterates Conviction Buy Rating on Golar LNG Ltd. (GLNG)
• MoffettNathanson Starts SpaceX (SPCX) at Neutral, 'Moats, Flywheels, and Unknown Unknowns'
• Active options: PLTR AMD IREN GOOGL AVGO MSTR WULF NFLX BMNR HOOD